Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly higher for patients without versus with type 2 diabetes (64.8% vs 46.5%), reported Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania in Philadelphia, and colleagues.

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these popular medications.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, Mounjaro and Zepbound.

Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for people struggling to lose weight. These drugs reduce appetite and sometimes slow digestion which

Josh Gad has opened up for the first time about using GLP-1 medication for weight loss and his seesaw experience with the positive and negative side effects.

Frozen’s Josh Gad shared insight into his weight loss journey after losing 40 pounds with the help of medication.